CXCL10/IP-10/CRG-2 Antibody

ELISA: CXCL10/IP-10/CRG-2 Antibody [26120002]

Product Discontinued

CXCL10/IP-10/CRG-2 Antibody Summary

• Immunogen: This antibody is specific for the entire range of the target protein.
• Specificity: This product is specific for Human CXCL10/INP10
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: CXCL10
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • ELISA 1:100-1:2000
• Application Notes: This antibody is useful in ELISA.

Reactivity Notes

Human.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: 20mM Potassium Phosphate (pH 7.0) and 0.15M NaCl
• Preservative: No Preservative
• Purity: Immunogen affinity purified

Notes

Manufactured by SDIX's proprietary Genomic Antibody Technology™. GAT FAQs.

Alternate Names for CXCL10/IP-10/CRG-2 Antibody

• C7
• chemokine (C-X-C motif) ligand 10
• CRG2
• CRG-2
• CXCL10
• gIP-10
• IFI10
• INP10
• IP-10
• mob-1
• SCYB10

Background

The monoclonal antibody 6D4 recognizes human C-X-C motif chemokine 10 (IP-10), a protein of 98 amino acids. IP-10, also known as CXCL10, functions as ligand for the CXCR3 receptor. IP-10 belongs to the a-chemokine (C-X-C) family, which can be divided in two subfamilies: (1) potent chemoattractants for neutrophils, like IL-8 and (2) potent chemoattractants for lymphocytes, like the IFNg inducible protein (IP)-10. IP-10 is produced by a wide variety of cell types ranging from neutrophils, dendritic cells and monocytes to hepatocytes, endothelial cells and keratinocytes. The cytokine is reported to be involved in a scala of inflammatory pathologies such as HIV, encephalitis, cutaneous T cell lymphoma, chronic hepatitis, psoriasis and acute anterior uveitis. Various observations strongly suggest a role for the C-X-C chemokines IL-8 and IP-10 in the regulation of angiogenic activity in cancer and in idiopathic pulmonary fibrosis. Furthermore IP-10 is associated with acute rejection processes estimated by the predictive properties of urinary IP-10 expression for the short- and long-term graft function after kidney transplantation.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CXCL10/IP-10/CRG-2 Antibody (26120002)(2)

Publications using 26120002

• Garrison C, Lastwika K, Zhang Y et al. Proteomic Analysis, Immune Dysregulation, and Pathway Interconnections With Obesity J Proteome Res. 2017-01-06 [PMID: 27769113] (MiAr)
  
  Details:
  Analysis is performed on plasma proteomic data to identify how obesity can alter pathways and to highlight the risk factor for disease in subjects with a high body mass index.
• Rho JH, Lampe PD. High-throughput screening for native autoantigen-autoantibody complexes using antibody microarrays J Proteome Res. 2013-05-03 [PMID: 23541305] (MiAr)
  
  Details:
  A novel method using antibody microarrays is used to detect autoantibody-antigen complexes that can potentially be useful for detection and characterization of diseases.

Bioinformatics

• Gene Symbol: CXCL10
• Entrez:
  • 3627(Human)
• Uniprot:
  • P02778()